Due to the actions of a 3rd party, our laboratory software is unable to process orders at our normal capacity. This is not a data breach. If this affects your laboratory orders, we will contact you directly. You do not need to call the practice.

About Us

Dr. Tedesco discusses first immunotherapy regimen for breast cancer

9/03/2019

Karen Tedesco, MD, was recently featured on the American Society of Clinical Oncology's national "Daily News" podcast.  She discusses the advancement in breast cancer treatment that came earlier this year, when the FDA granted accelerated approval to atezolizumab, the first cancer immunotherapy regimen for breast cancer.

In addition to treating patients, Karen Tedesco, MD, also serves as principal investigator at NYOH for clinical trials related to breast cancer treatment. In the nine-minute podcast, she also discusses how the IMpassion 130 study will continue to inform treatment of metastatic triple negative breast cancer. 

Listen